N- (2- (4- (4,9- diethoxy- 1- oxo- 1,3- dihydro- 2H- benzo(f)isoindol- 2- yl)phenyl)acetyl)benzene sulphonamide

structure in first source

Also Known As:

GW627368X

Networked: 4 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amides: 2428
  - Sulfonamides: 2809
    - N-(2-(4-(4,9-diethoxy-1-oxo-1,3-dihydro-2H-benzo(f)isoindol-2-yl)phenyl)acetyl)benzene sulphonamide: 4
- Sulfur Compounds: 278
  - Sulfones: 534
    - Sulfonamides: 2809
      - N-(2-(4-(4,9-diethoxy-1-oxo-1,3-dihydro-2H-benzo(f)isoindol-2-yl)phenyl)acetyl)benzene sulphonamide: 4
Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Isoindoles: 18
      - N-(2-(4-(4,9-diethoxy-1-oxo-1,3-dihydro-2H-benzo(f)isoindol-2-yl)phenyl)acetyl)benzene sulphonamide: 4

Experts

1.	Bharti, R: 1 article (03/2016)
2.	Das, S: 1 article (03/2016)
3.	Mandal, M: 1 article (03/2016)
4.	Pal, I: 1 article (03/2016)
5.	Parekh, A: 1 article (03/2016)
6.	Parida, S: 1 article (03/2016)
7.	Thakur, B: 1 article (03/2016)
8.	Bek, Toke: 1 article (08/2015)
9.	Kringelholt, Sidse: 1 article (08/2015)
10.	Oversø Hansen, Pernille: 1 article (08/2015)

Related Diseases

1.	Uterine Cervical Neoplasms (Cancer of the Cervix) 03/24/2016 - "GW627368X inhibits proliferation and induces apoptosis in cervical cancer by interfering with EP4/EGFR interactive signaling." 03/24/2016 - "The present study demonstrates GW627368X, a highly selective competitive EP4 antagonist, which hinders cervical cancer progression by inhibiting EP4/epithelial growth factor receptor (EGFR) interactive signaling. "
2.	Neoplasms (Cancer) 03/24/2016 - "GW627368X therefore effectively inhibits tumor survival, motility, proliferation and angiogenesis by blocking EP4/EGFR interactive signaling. " 01/01/2008 - "The selective EP4 antagonist, GW627368X, induced inhibition of proliferation and invasion of human SUM149 IBC tumor cells beginning at 0.1 microM, with inhibition of proliferation and invasion by MDA-MB-231 non-IBC cells at higher concentrations of GW627368X. " 01/01/2015 - "Oral administration of GW627368X showed significant tumor regression characterized by tumor reduction and induction of apoptosis. "
3.	Sarcoma (Soft Tissue Sarcoma) 01/01/2015 - "Molecular inhibition of prostaglandin E2 with GW627368X: Therapeutic potential and preclinical safety assessment in mouse sarcoma model."
4.	Hypoxia (Hypoxemia) 08/01/2015 - "The simultaneous addition of L-NAME or 1400W in combination with ibuprofen, but not GW627368X, reduced hypoxia-induced vasorelaxation additively as compared to the effect of the compounds individually. " 08/01/2015 - "Porcine retinal arterioles with preserved perivascular retinal tissue were mounted in a myograph and were exposed to hypoxia in the presence of one of the following: the general NO synthase inhibitor L-NAME, the selective iNOS inhibitor 1400W, the selective nNOS inhibitor 7-nitroindazole, the general cyclooxygenase (COX) inhibitor ibuprofen or an antagonist to the FP- (AL 8810), DP- (BWA868C), EP1 - (SC-19220), EP2 - (PF-044189) or EP4 receptors (GW627368X). "

Related Drugs and Biologics

1.	Growth Factor Receptors
2.	NG-Nitroarginine Methyl Ester (L-NAME)
3.	Nitric Oxide Synthase (NO Synthase)
4.	Dinoprostone (PGE2)
5.	Retinaldehyde (Retinal)
6.	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)
7.	Ibuprofen (Motrin)
8.	AL 8810
9.	7-nitroindazole
10.	BW A868C

Related Therapies and Procedures

1.	Oral Administration